In 2010, SHL introduced customers to a new drug-device development model with the preconfigured Molly 1ml. The preconfigured technology offered customers a faster development timeline while reducing costs for their combination products. Staying at the forefront of the drug-device industry, SHL has since advanced its offerings in providing Molly 2.25, which is built with bigger volume capacity yet still equipped with the same robust technology.
While biologics are expected to make up more than half of the world's top 100-selling drugs by 2020, the pharmaceutical industry is seeking opportunities to deliver highly viscous or high-volume drugs for self-treatment in a timely manner. By launching Molly 2.25, SHL addresses the rapid growth of largemolecular products, providing an auto injector that can accommodate syringes up to 2.25ml.
Through years of observation and in-depth research, SHL experts created a development strategy for customers seeking faster pathways to launch their auto injector project. Designers rose to the challenge of developing an easy-to-use, ready-made device with a usability focus to the patient's comfort, answering with a compact auto injector designed with preconfigured technology.
This strategy helped reduce product development time, eliminating many hurdles that developers so often encountered during the early design stage.
Molly's flexible business model offers customers the opportunity to minimise investments by cutting down major individual investments in tooling, assembly, and/or testing equipment. Customers are offered different levels of customisation, in which they choose from a selection of component designs depending on their pre-filled syringe, fill volume and drug formulation.
An additional factor that expedites the Molly auto injector production process comes from SHL's vertical integration of key manufacturing capabilities that facilitates parallel development of automation and assembly systems. SHL's in-house automation capabilities drive a robust assembly line for production scaleup, enabling SHL the capacity to meet the rapidly growing market demands. Commenting on SHL's automation systems, SHL director of automation Lucy Chung says, "Years of dedication has enabled us to produce fully- automated assembly and testing systems that will upgrade Molly's production."
Numerous usability trials reveal that users prefer smaller devices and less frequent injections. Thus, SHL managed to keep the slightly larger Molly 2.25 handy and lightweight, ensuring an easy handling experience without sacrificing patient preference. The bigger Molly owns a similar design to Molly 1ml, yet is built with a slightly larger body so as to accommodate the 2.25ml syringe. The larger size, however, is far from any notion of bulkiness, maintaining the original Molly's design feature of being portable and compact.
Adeptly designed, the Molly 2.25 architect comes with a rectangular, easy-to-pull cap that prevents the rolling motion inherently characterised in many round-cap auto injectors.
This strategic design is mainly aimed at preventing auto injector breakages from accidental drops.
Through combined efforts of designers, engineers, project managers, and business developers, the Molly 2.25 design continues to uphold SHL's high standards in the design and making of devices, while also proving SHL's ability to meet customer demands and patient needs.